NCT03681093

Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma

A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Fevipiprant Once Daily Plus Standard-of-care (SoC) for Assessment of the Efficacy in Reduction of Nasal Polyp Size in Patients With Nasal Polyposis and Concomitant Asthma.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 98 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A Phase 3b Proof-of-Concept study to evaluate the ability of fevipiprant 150 mg and 450 mg, compared with placebo, as add-on to nasal spray standard-of-care (SoC), in reducing endoscopic nasal polyp score in adult (≥ 18 years) patients with nasal polyposis and concomitant asthma.

Detailed description

This was a Phase 3b, Proof-of-concept study with a randomized, multicenter, double-blind, placebo-controlled, parallel-group study design to determine the ability of fevipiprant plus standard of care (SoC) compared to placebo plus SoC to reduce the size of nasal polyps. The study enrolled adult male and female patients diagnosed with nasal polyposis with a nasal polyp score assessed by nasal endoscopy ≥ 4 at baseline with a minimum score of 2 in each nostril and a concomitant diagnosis of asthma. Patients who meet the inclusion/exclusion criteria were randomized in 1:1:1 ratio in either of the 3 arms fevipiprant 450 mg dose once daily (o.d.), fevipiprant 150 mg dose o.d. or placebo o.d. in addition to SoC (mometasone furoate spray). The study included: * a Screening period of 2 weeks to assess eligibility * a Run-in period of 4 weeks where patients utilized mometasone furoate spray (200 μg once daily, administered as two 50 μg actuations into each nostril) * a Treatment period of 16 weeks. Patients continued to use the mometasone furoate SoC throughout the treatment period. * a Follow-up period of 2 weeks following the last dose of study drug to collect additional data for safety variables. The purpose of this study was to evaluate the efficacy and safety of fevipiprant 150 mg and 450 mg compared to placebo in the reduction of nasal polyps size and the effect on symptoms, quality of life and smell via patient-reported outcomes in patients with nasal polyposis and concomitant asthma.

Conditions

• Nasal Polyps

Interventions

Type	Name	Description
DRUG	Fevipiprant 150 mg	Fevipiprant (QAW039) 150 mg once daily administered orally as tablet
DRUG	Fevipiprant 450 mg	Fevipiprant (QAW039) 450 mg once daily administered orally as tablet
DRUG	Placebo	Placebo once daily administered orally as tablet

Timeline

• Start date: 2019-03-26
• Primary completion: 2020-05-29
• Completion: 2020-06-10
• First posted: 2018-09-21
• Last updated: 2021-10-11
• Results posted: 2021-01-05

Locations

25 sites across 9 countries: United States, Argentina, Belgium, Canada, Czechia, Germany, Italy, Netherlands, Poland

Regulatory

• FDA-regulated drug study